|
GRN-529 is a research drug that was developed by Wyeth as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5).〔(【引用サイトリンク】url=http://www.google.com/patents/US20100273772.pdf )〕 A study conducted by Pfizer found that GRN-529 reduced repetitive behaviors without sedation and partially increased sociability in mouse models of autism. 〔 〕 Another study conducted by Pfizer found a therapeutically relevant effect in animal models of depression. It is theorized to work by reducing glutamate receptor hyperactivity.〔 〕 ==See also== * Fenobam * MPEP * MTEP 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「GRN-529」の詳細全文を読む スポンサード リンク
|